Fig. 2From: Strong synergy with APR-246 and DNA-damaging drugs in primary cancer cells from patients with TP53 mutant High-Grade Serous ovarian cancerInhibition of cell viability by APR-246 (a) and cisplatin (b). Cell viability was assessed by the FMCA assay after 72 h incubation with drug. The results shown are mean ± SEM; n = 10 patientsBack to article page